Abstract: Embodiments of the disclosure provide a method for manufacturing a semiconductor device. The method includes: providing a substrate having at least one trench; forming a first polysilicon layer in the trench, covering a sidewall and a bottom of the trench and not fully fills the trench; annealing the first polysilicon layer; and forming a second polysilicon layer at a region of the trench where the first polysilicon layer is not filled after annealing.

Abstract: Yes-associated protein (Yap), a downstream co-activator of the Hippo pathway, is highly expressed in the Treg cell subset, and is critical to maintain its suppressive activity. Originally discovered in Drosophila melanogaster, the Hippo signaling pathway is a major regulator of cellular growth and proliferation in mammals. Loss of Yap expression in Treg cells can lead to superior anti-tumor immune responses, and thus, Yap is an important immunotherapeutic target for cancer.

Abstract: The present disclosure provides a method and an apparatus for application communication and a storage medium. The specific implementation scheme is: in a process of a first application in a vehicle machine needing to control a second application, the first application may send a notification message including a key-value pair to a second application through a state machine in the vehicle machine, so that when the second application receives a notification message sent by the first application through a state machine, a corresponding operation may be performed by the key-value pair in the notification message.

Abstract: The disclosure provides example block generation methods. One example method includes that when a first blockchain node is a leader, packing, by the first blockchain node, a leader-elected transaction in a transaction pool into a first block, where the leader-elected transaction records a leader proof of the first blockchain node. The leader proof records a voting state in which each of the plurality of second blockchain nodes votes on the first blockchain node, and the voting state indicates whether a vote is a positive vote or a negative vote. Sends the first block to the plurality of second blockchain nodes, so that the first blockchain node and/or the second blockchain nodes perform fork processing based on the leader proof.

Abstract: The present invention relates to compositions and methods for treating cancer by targeting the Activin signaling pathway. In certain embodiments, combining Activin blockade with immunomodulation alters regulatory T (Treg) cell-mediated immune regulation and treats cancer.

Abstract: The present invention relates to compositions and methods for treating cancer by targeting the Activin signaling pathway. In certain embodiments, combining Activin blockade with immunomodulation alters regulatory T (Treg) cell-mediated immune regulation and treats cancer.

Abstract: We demonstrate herein that neuritin controls the homeostasis of regulatory T cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory T cells in various disease settings is described. Thus manipulation of Treg cells and DCs through neuritin can be used to enhance immunotherapy of autoimmune diseases, cancer and infectious diseases, as well as enhance lymphocyte engraftment in settings of donor lymphocyte infusion, bone marrow transplant, as well as other types of transplants, and adoptive transfer.

Abstract: The present invention relates to compositions and methods for treating cancer by targeting the Activin signaling pathway. In certain embodiments, combining Activin blockade with immunomodulation alters regulatory T (Treg) cell-mediated immune regulation and treats cancer.

Abstract: The present invention relates to novel compositions and methods to produce 3D organ equivalents of the brain (i.e. “mini-brains”). The invention also relates to methods of using human induced pluripotent stem cells, a combination of growth and other soluble factors and gyratory shaking. Cells from healthy or diseased donors or animals can be used to allow testing different genetic backgrounds. The model can be further enhanced by using genetically modified cells, adding micro-glia or their precursors or indicator cells (e.g. with reporter genes or tracers) as well as adding endothelial cells to form a blood-brain-barrier.

Abstract: Yes-associated protein (Yap), a downstream co-activator of the Hippo pathway, is highly expressed in the Treg cell subset, and is critical to maintain its suppressive activity. Originally discovered in Drosophila melanogaster, the Hippo signaling pathway is a major regulator of cellular growth and proliferation in mammals. Loss of Yap expression in Treg cells can lead to superior anti-tumor immune responses, and thus, Yap is an important immunotherapeutic target for cancer.

Abstract: A portable electronic device includes a display, a sliding track, a hinge, and a host. The display has a receiving groove. The sliding track is disposed in the display, and faces the receiving groove. The hinge is movably disposed on the sliding track, and located in the receiving groove. The host is disposed on the hinge. The host is rotated and moved relative to the display via the hinge. When the portable electronic device is in a tablet mode, the host is located in the receiving groove, and sustainably parallel to the display.

Abstract: A portable electronic device includes a display, a sliding track, a hinge, and a host. The display has a receiving groove. The sliding track is disposed in the display, and faces the receiving groove. The hinge is movably disposed on the sliding track, and located in the receiving groove. The host is disposed on the hinge. The host is rotated and moved relative to the display via the hinge. When the portable electronic device is in a tablet mode, the host is located in the receiving groove, and sustainably parallel to the display.

Abstract: The present invention provides compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein each of W, Q, R1, R2, R3, R4, R5, m, and n is as defined herein, pharmaceutically acceptable compositions thereof, and methods of using the same.

Abstract: Use of an ubiquitination pathway-related factor, its agonist or antagonist in the preparation of a composition for regulating FOXP3, IL-2, and/or IFN-? activity, in which the ubiquitination pathway-related factor is selected from: Toll-like receptor, ubiquitin ligase, pro-inflammatory cytokine family receptor, and/or its coding sequence. The new type of regulatory factors can regulate regulatory T cells and immune system by regulating FOXP3, IL-2, and/or IFN-? activity. The regulatory factors and their derivatives can also be used as immunoadjuvant for treating or preventing major diseases (such as, infectious diseases and tumor, etc).

Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Abstract: This invention relates to a new use of a compound of the following formula (I) or (II) for the manufacture of a medicament for preventing and/or treating chronic rejection in a transplanted organ or tissue.

Abstract: This invention relates to a new use of a compound of the following formula (I) or (II) for the manufacture of a medicament for preventing and/or treating chronic rejection in a transplanted organ or tissue.